Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106002 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00106002 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 37 participants.
The verdict
NCT00106002, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purposes of this study are to determine whether pemetrexed can help patients with metastatic (cancer that has spread to other parts of the body) breast cancer, to determine any side effects that may be associated with the drug, to determine how much pemetrexed should be given to patients, and to collect DNA for future research regarding metastatic breast cancer. The collection of DNA is optional to the patient.
Interventions
- DRUG pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106002
The ClinicalTrials.gov registry entry for NCT00106002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pemetrexed is the first listed.
NCT00106002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106002 about?
NCT00106002 is a clinical study titled "Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer". The purposes of this study are to determine whether pemetrexed can help patients with metastatic (cancer that has spread to other parts of the body) breast cancer, to determine any side effects that may be associated with the drug, to determine how much pemetrexed should be given to patients, and to...
What is the current status of trial NCT00106002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2005-04. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00106002?
The interventions under investigation include: pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00106002?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.